Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
NIS793 + spartalizumab + gemcitabine + nab-paclitaxel is a four-drug investigational combination therapy for advanced and metastatic solid tumors, particularly pancreatic and colorectal cancers. - **NIS793** is a human IgG2 monoclonal antibody that binds and neutralizes transforming growth factor beta (TGF-β1 and TGF-β2), inhibiting TGF-β signaling implicated in tumor progression and microenvironment immunosuppression[1][3]. - **Spartalizumab** is a monoclonal antibody inhibitor of programmed cell death protein 1 (PD-1), serving as a checkpoint inhibitor that removes brakes on anti-tumor immune responses[1][3]. - **Gemcitabine** is a nucleoside analog antimetabolite chemotherapeutic that inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells[6]. - **Nab-paclitaxel** is an albumin-bound formulation of the microtubule inhibitor paclitaxel, enhancing delivery to tumors and disrupting mitosis[2][4][6]. The combination is designed to integrate inhibition of immunosuppressive signaling (TGF-β blockade), immune checkpoint inhibition (PD-1 blockade), and cytotoxic chemotherapy for synergistic activity.
- Other names
- NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)PDCD1 (Programmed cell death protein 1 receptor)TGFB3 (Transforming growth factor beta 3)TGFB2 (Transforming growth factor beta 2)TUBB (Tubulin (alpha and beta subunits))RRM1
Beyond the preview
Go deeper on NIS793 + spartalizumab + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIS793 + spartalizumab + gemcitabine + nab-paclitaxel.